23 completed, 2 active not recruiting, 2 unknown, 1 withdrawn. 28 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 23, Active not recruiting 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow ixekizumab: new trials by email Literature Review of ixekizumab trials Research Report on ixekizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy Picankibart, Secukinumab, Placebo - Plaque Psoriasis | Phase 3 | Active not recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 308 | 2025-05-27 | 2026-03-25 |
| Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis Ixekizumab - Guttate Psoriasis | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2025-05-01 | 2025-02-10 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriasis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 281 | 2024-09-30 | 2026-06-17 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriatic Arthritis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 279 | 2024-09-24 | 2026-05-13 |
| A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis Ixekizumab, Adalimumab - Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | Phase 3 | Active not recruiting | Eli Lilly and Company | 101 | 2021-04-13 | 2026-08-12 |
| Survival TRial Using CytoKines in COVID-19 (STRUCK Trial) Ixekizumab, Aldesleukin, Colchicine - Covid19 | Phase 3 | Completed | University of Sao Paulo | 60 | 2021-01-05 | 2022-07-28 |
| Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis Prednisolone, Sulfasalazine, Leflunomide - Psoriatic Arthritis, Withdrawal | Phase 3 | Unknown | University of Erlangen-Nürnberg Medical School | 270 | 2020-10-19 | 2022-11-14 |
| A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis Ixekizumab, Placebo - Spondyloarthritis | Phase 3 | Completed | Eli Lilly and Company | 147 | 2020-04-10 | 2023-04-14 |
| A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis Ixekizumab, Placebo - Plaque Psoriasis | Phase 3 | Completed | Eli Lilly and Company | 438 | 2018-04-26 | 2021-06-25 |
| A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Ixekizumab, Placebo - Axial Spondyloarthritis | Phase 3 | Completed | Eli Lilly and Company | 773 | 2017-05-09 | 2022-06-13 |
| Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Ixekizumab, Placebo, Etanercept - Plaque Psoriasis | Phase 3 | Completed | Eli Lilly and Company | 201 | 2017-03-28 | 2021-09-27 |
| A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Ixekizumab, Placebo - Axial Spondyloarthritis | Phase 3 | Completed | Eli Lilly and Company | 303 | 2016-08-02 | 2020-03-13 |
| A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Ixekizumab, Placebo, Adalimumab - Spondyloarthritis | Phase 3 | Completed | Eli Lilly and Company | 341 | 2016-05-02 | 2019-11-19 |
| A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Ixekizumab, Placebo - Spondyloarthritis | Phase 3 | Completed | Eli Lilly and Company | 316 | 2016-04-12 | 2020-06-17 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Ixekizumab, Placebo - Genital Psoriasis, Psoriasis | Phase 3 | Completed | Eli Lilly and Company | 149 | 2016-04-01 | 2019-09-16 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment Fumaric Acid Esters, Methotrexate, Ixekizumab - Plaque Psoriasis | Phase 3 | Completed | Eli Lilly and Company | 162 | 2016-01-20 | 2019-10-09 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Ixekizumab, Ustekinumab, Placebo - Plaque Psoriasis | Phase 3 | Completed | Eli Lilly and Company | 302 | 2015-10-01 | 2020-06-17 |
| A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis Ixekizumab, Placebo - Psoriatic Arthritis | Phase 3 | Completed | Eli Lilly and Company | 394 | 2015-09-14 | 2019-11-15 |
| A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Ixekizumab, Placebo - Plaque Psoriasis | Phase 3 | Completed | Eli Lilly and Company | 1257 | 2015-08-01 | 2020-06-17 |
| A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis Ixekizumab - Psoriasis | Phase 3 | Completed | Eli Lilly and Company | 12 | 2015-04-01 | 2019-09-18 |
Showing 20 of 28. Sign in to see all of them.
Psoriasis (7) · Arthritis, Psoriatic (5) · Spondylarthritis (4) · Spondylitis, Ankylosing (4) · Axial Spondyloarthritis (2) · Obesity (2) · Arthritis, Juvenile (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Guttate Psoriasis (1) · Pruritus (1) · Skin Diseases (1) · Spondylarthropathies (1)
Eli Lilly and Company (24) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University of Erlangen-Nürnberg Medical School (1) · University of Sao Paulo (1)
United States (18) · Germany (15) · Poland (13) · Canada (12) · Czechia (11) · Netherlands (11) · Mexico (10) · Spain (10) · United Kingdom (10) · France (9) · Puerto Rico (9) · Argentina (8) · Japan (8) · Hungary (7) · Russia (7)
Eduardo Ramacciotti, MD, PhD (1) · Esper Kallas, MD, PhD (1) · Fernando Rodrigues, MD, PhD (1) · Leandro B Agati, PhD (1) · Renato D Lopes, MD, PhD (1)
PMID 35279805, PMID 36792107, PMID 37400681, PMID 26953848, PMID 27299809, PMID 31964419, PMID 35393269, PMID 35429281, PMID 36282526, PMID 38521874, PMID 38647975, PMID 40694276, PMID 41417207, PMID 26072109, PMID 28074446, PMID 30465321, PMID 30696483, PMID 30886974, PMID 31154634, PMID 31254223, PMID 31685553, PMID 32200512, PMID 32792421, PMID 32845588, PMID 33499913, PMID 34538257, PMID 34853086, PMID 35188180, PMID 35397092, PMID 38814433, PMID 38955921, PMID 40014255, PMID 42228347, PMID 25355284, PMID 27500949, PMID 27553214, PMID 27910156, PMID 28551073, PMID 29247148, PMID 29299340, PMID 29751001, PMID 29945203, PMID 30053162, PMID 30343531, PMID 31376153, PMID 31813637, PMID 32031665, PMID 32415575, PMID 32910360, PMID 33044756
2015 (8), 2016 (2), 2018 (1), 2023 (1)